About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Renaissance Pharma Acquires Cold Sore Treatment Denavir®

Establishes New Subsidiary to Commercialize Product; Appoints Industry Leaders to Executive Positions

NEWTOWN, Pa., Aug. 15, 2012 /PRNewswire/ — Renaissance Pharma, Inc. (“Renaissance”), a RoundTable Healthcare Partners portfolio company, announced today that it has acquired certain assets and the US rights to manufacture, market and sell Denavir®  (1% penciclovir cream) from investment funds managed by Deerfield Management Company (“Deerfield”) and New American Therapeutics, Inc., a Deerfield portfolio company.  Denavir is a topical antiviral indicated for the treatment of recurrent herpes labialis (cold sores) in adults and children 12 years of age and older.  More information on Denavir can be found at

Renaissance is focused on acquiring, developing, manufacturing, and marketing niche prescription pharmaceuticals across a variety of dosage forms and therapeutic categories.  With the acquisition of Denavir, Renaissance has established a new subsidiary, Prestium Pharma (“Prestium”), focused on commercializing branded products in the US.  Pierre Frechette, the President and CEO of Renaissance stated, “We are enthusiastic about the acquisition of our first branded product and the creation of Prestium, and look forward to further expanding our product portfolio.”

To support the execution of Renaissance’s strategy, two key individuals have been appointed to the Renaissance team.  John Denman, a pharmaceutical industry veteran for over 25 years, has been named General Manager of Prestium.  Before joining Prestium, Mr. Denman held increasing levels of responsibility at Teva Pharmaceuticals where he most recently was responsible for all aspects of its US commercial operations including sales, marketing, R&D, and business development.  Prior to Teva, Mr. Denman was at Sandoz in a senior level marketing position.

“I am thrilled to join Prestium and to have Denavir as our first branded offering,” said Mr. Denman.  “Denavir is an important product as it offers patients a proven therapy for the treatment of cold sores, an embarrassing, uncomfortable, and often unpredictable condition.” 

Earlier this year, Ray Canole joined Renaissance as Vice President of Business Development.  Mr. Canole worked in a variety of business and corporate development roles for the past ten years at Perrigo Company, where he helped lead over 20 acquisitions and numerous product collaborations for their prescription drug segment.

“This is an exciting time in the specialty pharmaceutical market, and I am pleased to have the opportunity to work with such an accomplished group of healthcare executives at both Renaissance and RoundTable,” commented Mr. Canole.  “With the acquisition of Denavir, Prestium is off to a great start and we are already at work pursuing additional product acquisitions.”

About Renaissance Pharma, Inc.

Renaissance Pharma, Inc., Newtown, PA, is a RoundTable Healthcare Partners portfolio company founded in 2010.  Renaissance is focused on acquiring, developing, manufacturing and marketing high quality, niche generic prescription pharmaceuticals across a variety of dosage forms and therapeutic categories. 

Prestium Pharma, Inc., a subsidiary of Renaissance, focuses on acquiring and selling in-market branded prescription products, including mature brands with or without generic competition.  More information about Renaissance can be found at